BioSyent Inc. (CVE:RX - Free Report) - Stock analysts at Bloom Burton cut their FY2026 earnings per share (EPS) estimates for shares of BioSyent in a research report issued to clients and investors on Tuesday, May 20th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.86 per share for the year, down from their previous forecast of $0.88. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent's FY2027 earnings at $0.93 EPS.
BioSyent Stock Up 0.4%
Shares of BioSyent stock traded up C$0.05 during midday trading on Wednesday, hitting C$12.00. The company had a trading volume of 2,938 shares, compared to its average volume of 4,726. BioSyent has a 52-week low of C$8.97 and a 52-week high of C$12.13. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The stock has a market capitalization of C$137.25 million, a P/E ratio of 19.48 and a beta of 0.93. The company has a 50 day moving average of C$10.84 and a 200 day moving average of C$11.07.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
